Success Metrics

Active Trials
3(50%)

Phase Distribution

Ph phase_3
3
50%
Ph phase_1
3
50%

Phase Distribution

3

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Other(1)

Detailed Status

Recruiting3
Not yet recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 33 (50.0%)

Trials by Status

not_yet_recruiting233%
unknown117%
recruiting350%

Recent Activity

3 active trials
Showing 5 of 6
not_yet_recruitingphase_3

A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer

NCT07802821
recruitingphase_1

A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients

NCT06911827
recruitingphase_1

A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

NCT07256782
not_yet_recruitingphase_3

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

NCT07162883
recruitingphase_3

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

NCT06754644
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07802821Phase 3

A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer

Not Yet Recruiting
NCT06911827Phase 1

A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients

Recruiting
NCT07256782Phase 1

A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

Recruiting
NCT07162883Phase 3

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

Not Yet Recruiting
NCT06754644Phase 3

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

Recruiting
NCT06173011Phase 1

A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6